Zobraziť v EDS

Improving value of care for renal cell carcinoma patients; development of a decision aid for metastatic clear-cell renal cell carcinoma.

Uložené v:
Podrobná bibliografia
Názov: Improving value of care for renal cell carcinoma patients; development of a decision aid for metastatic clear-cell renal cell carcinoma.
Autori: Bresser CC; St. Antonius Hospital, Dept. of Urology, Nieuwegein, the Netherlands; St. Antonius Hospital, Dept. of Value Improvement, Nieuwegein, the Netherlands; Radboudumc, IQ Health, Nijmegen, the Netherlands. Electronic address: c.bresser@antoniusziekenhuis.nl., van Melick HHE; St. Antonius Hospital, Dept. of Urology, Nieuwegein, the Netherlands., The R; ZorgKeuzeLab, Delft, the Netherlands., van der Nat PB; St. Antonius Hospital, Dept. of Value Improvement, Nieuwegein, the Netherlands; Radboudumc, IQ Health, Nijmegen, the Netherlands., Garvelink MM; St. Antonius Hospital, Dept. of Value Improvement, Nieuwegein, the Netherlands; Radboudumc, IQ Health, Nijmegen, the Netherlands.
Zdroj: Patient education and counseling [Patient Educ Couns] 2025 Aug; Vol. 137, pp. 108800. Date of Electronic Publication: 2025 Apr 29.
Spôsob vydávania: Journal Article
Jazyk: English
Informácie o časopise: Publisher: Elsevier Country of Publication: Ireland NLM ID: 8406280 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-5134 (Electronic) Linking ISSN: 07383991 NLM ISO Abbreviation: Patient Educ Couns Subsets: MEDLINE
Imprint Name(s): Publication: Limerick : Elsevier
Original Publication: Princeton, N.J. : Excerpta Medica, c1983-
Výrazy zo slovníka MeSH: Carcinoma, Renal Cell*/therapy , Carcinoma, Renal Cell*/psychology , Kidney Neoplasms*/therapy , Kidney Neoplasms*/pathology , Kidney Neoplasms*/psychology , Decision Support Techniques* , Patient Participation* , Decision Making, Shared*, Humans ; Male ; Female ; Middle Aged ; Aged ; Adult ; Needs Assessment ; Patient-Centered Care ; Decision Making
Abstrakt: Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: RT works for ZorgKeuzeLab; a company that supported the development of this patient decision aid. Other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Objective: Patient decision aids (PtDAs) can support shared decision-making (SDM) by providing information about options, pros and cons and eliciting personal preferences. The aim of this study was to develop and test the acceptability and usability of a PtDA for patients with metastatic clear-cell renal cell carcinoma (RCC), the most common type of metastatic kidney cancer.
Methods: User-centered mixed methods design. Co-creation process with stakeholders guided by the International Patient Decision Aids Standards (IPDAS) criteria, consisting of three main elements: (a) a needs assessment; (b) acceptability and usability testing; and (c) compatibility assessment with IPDAS criteria.
Results: Thirteen RCC patients and 29 healthcare professionals (HCP) participated in this study. Co-creation sessions were held with nine HCPs and a patient representative. Needs assessment (a) showed that patients lacked real treatment choices and wanted information on all treatment options, including life expectancy, side effects, psychological, and lifestyle advice. HCPs expect a PtDA to improve information delivery and patient engagement. A three-component PtDA was developed and tested (b), with positive feedback from both patients and professionals. The tool meets all 12 IPDAS criteria (c).
Conclusions: The web-based PtDA was developed and adapted to address unmet needs and found to be acceptable and usable by patients and HCPs.
Practice Implications: The use of this tool could contribute to high quality, patient-centered and appropriate care for metastatic clear cell RCC patients in the Netherlands.
(Copyright © 2025 The Authors. Published by Elsevier B.V. All rights reserved.)
Contributed Indexing: Keywords: Decision aid; Metastatic clear-cell renal cell carcinoma; Shared decision-making
Entry Date(s): Date Created: 20250502 Date Completed: 20250609 Latest Revision: 20250609
Update Code: 20250611
DOI: 10.1016/j.pec.2025.108800
PMID: 40315706
Databáza: MEDLINE
Popis
Abstrakt:Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: RT works for ZorgKeuzeLab; a company that supported the development of this patient decision aid. Other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.<br />Objective: Patient decision aids (PtDAs) can support shared decision-making (SDM) by providing information about options, pros and cons and eliciting personal preferences. The aim of this study was to develop and test the acceptability and usability of a PtDA for patients with metastatic clear-cell renal cell carcinoma (RCC), the most common type of metastatic kidney cancer.<br />Methods: User-centered mixed methods design. Co-creation process with stakeholders guided by the International Patient Decision Aids Standards (IPDAS) criteria, consisting of three main elements: (a) a needs assessment; (b) acceptability and usability testing; and (c) compatibility assessment with IPDAS criteria.<br />Results: Thirteen RCC patients and 29 healthcare professionals (HCP) participated in this study. Co-creation sessions were held with nine HCPs and a patient representative. Needs assessment (a) showed that patients lacked real treatment choices and wanted information on all treatment options, including life expectancy, side effects, psychological, and lifestyle advice. HCPs expect a PtDA to improve information delivery and patient engagement. A three-component PtDA was developed and tested (b), with positive feedback from both patients and professionals. The tool meets all 12 IPDAS criteria (c).<br />Conclusions: The web-based PtDA was developed and adapted to address unmet needs and found to be acceptable and usable by patients and HCPs.<br />Practice Implications: The use of this tool could contribute to high quality, patient-centered and appropriate care for metastatic clear cell RCC patients in the Netherlands.<br /> (Copyright © 2025 The Authors. Published by Elsevier B.V. All rights reserved.)
ISSN:1873-5134
DOI:10.1016/j.pec.2025.108800